Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Table 3 Response rate and survival according to prognostic factors

Characteristic	Response CR/CRu/PR			1-year progression free survival			2-year overall survival
	N	%	P	N	%	P	N	%	P
Time to relapse after diagnosis, months
<12	33	35	<0.001	15	16	<0.001	7	7	<0.001
≥12	47	68		46	67		35	51
Prior rituximab treatment
No	63	67	<0.001	38	40	0.355	20	21	0.126
Yes	17	25		23	33		22	32
SaaIPI at relapse
2–3	16	27	<0.001	10	17	<0.001	5	9	<0.001
0–1	64	67		51	49		37	36
ALC/AMC ratio
<2.0	20	27	<0.001	9	12	<0.001	3	4	<0.001
≥2.0	60	67		52	58		39	43
Absolute monocyte count
≥530/ul	21	33	<0.001	13	20	<0.001	6	9	<0.001
<530/ul	59	60		48	49		36	36
Absolute lymphocyte count
<1120/ul	41	41	0.015	27	27	0.001	15	15	<0.001
≥1120/ul	39	61		34	53		27	42
LDH at relapse
>Normal	16	28	<0.001	12	21	0.001	9	16	0.026
≤Normal	64	61		49	47		33	31
Rituximab containing salvage therapy
No	55	46	0.166	39	33	0.036	22	18	<0.001
Yes	25	58		22	51		20	47

Abbreviations: CR complete remission, CRu unconfirmed complete remission, PR partial response, saaIPI second-line age-adjusted International Prognostic Index, ALC/AMC ratio absolute lymphocyte count/absolute monocyte count ratio, LDH lactate dehydrogenase.

ISSN: 1471-2407